The Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), has selected Australian drugmaker CSL Ltd’s (ASX: CSL) subsidiary CSL Seqirus to provide 665,000 pre-pandemic vaccine doses for 15 European Union and European Economic Area (EEA) member states as well as to the "Union Civil Protection Mechanism" (rescEU).
In addition, the four-year contract includes an option for participating authorities to purchase up to an additional 40 million doses of the pre-pandemic vaccine over the life of the contract.
The company noted that this acquisition of pre-pandemic (zoonotic) vaccine will create a stockpile of vaccines available to support the EC’s outbreak and pre-pandemic response. No financial details were disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze